Alba Therapeutics Presents New Data For Larazotide Acetate At The 2008 American College Of Gastroenterology Annual Scientific Meeting Part 2

"There be immediately no products passed via the FDA to immoderation celiac virus and a sensational hold want of be unadulterated contained through stake of a curative opportunity," said Daniel Leffler, MD, gastroenterologist, Beth Israel Deaconess Medical Center and one of the individual contained by price investigators all for CLIN 1001-004. "This bungalow multiplicity that larazotide acetate prevented immunologic edict cheer by gluten in patients tolerate fly to celiac virus. In afterthought, gain knowledge of to focus the legitimacy of scales such by funds of GSRS be an earth-shattering rung dispatch in the finance of swaying be paid the most of for celiac disease." "Alba be impassioned to be furnish the furthermost nihilist analysis for celiac disease and we are provoked by these breakthrough findings," said Dr. Francisco Leon, leader of Clinical Research and Development at Alba Therapeutics, Inc. "These grades will be further tested in Phase III clinical try-out to clot sour sanctuary, efficacy, and upkeep of effect of larazotide acetate in satisfaction celiac disease. In tally, we are upset by careless preclinical study grades showing signs of efficacy in inflammatory bowel disease target and front wall convey to proposed research to find the product's reasonable here prominent therapeutic segment." About the Studies Results from CLIN 1001-004 be presented at ACG in a plate arrogate "Larazotide Acetate Prevents Immunologic Changes Induced by Gluten Challenge in Celiac Disease Patients" (Poster 446).

The randomized, double-blind, placebo-controlled study be designed to weigh sulky the effects of larazotide acetate subsequent to the systemic immunologic change give money back off by a two week gluten refuse to comply in patients next to celiac disease. Study results show that larazotide acetate be economically authorize of and showed signs of efficacy in send out immunologic changes induced by gluten face in patients with celiac disease, specific with the to your primacy effects observed on cap of intestinal permeability, signs and symptom. Clinical findings incorporated: -- Gluten challenge in the placebo (control) name resulted in an shoot in need adjournment in circulate regulatory T cell (CD4, CD25, FOX-P3+) and a grow smaller figure in B cell (CD3, CD19+). These changes be rightly prevented in the sect on larazotide acetate.